Peter E. Soden
GlaxoSmithKline (United Kingdom)(GB)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Alzheimer's disease research and treatments, Multiple Myeloma Research and Treatments, Ubiquitin and proteasome pathways, Histone Deacetylase Inhibitors Research
Most-Cited Works
- → Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia(2011)1,506 cited
- → Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation(2020)416 cited
- → The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor(2014)187 cited
- → MAPK-activated Protein Kinase 2 Deficiency in Microglia Inhibits Pro-inflammatory Mediator Release and Resultant Neurotoxicity(2006)168 cited
- → Dishevelled Regulates the Metabolism of Amyloid Precursor Protein via Protein Kinase C/Mitogen-Activated Protein Kinase and c-Jun Terminal Kinase(2001)119 cited
- → Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer’s disease(2003)86 cited
- → GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins(2020)84 cited
- → The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes(2014)73 cited
- → Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease.(2008)66 cited
- → Discovery of Potent, Isoform-Selective Inhibitors of Histone Deacetylase Containing Chiral Heterocyclic Capping Groups and aN-(2-Aminophenyl)benzamide Binding Unit(2013)55 cited